Do Racial and Income Disparities Exist in the Application of 21‐Gene Recurrence Score?
No clinically significant disparities were observed in race or income level in the application of the 21-gene recurrence score, which is reassuring, particularly as chemotherapy treatment regimens continue to trend appropriately trend toward de-escalation. However, underuse was more evident among older patients, separated/divorced/widowed individuals, and those undergoing mastectomy, highlighting opportunities to improve equity and adherence to guideline-based testing.
Authors
- Abhishek Chatterjee (ORCID: https://orcid.org/0000-0002-8003-7991)
- Caroline King (ORCID: https://orcid.org/0000-0002-9913-6340)
- Alanna Hickey
- K. Araujo Torres
- Camila Franco-Mesa (ORCID: https://orcid.org/0000-0001-6125-6825)
- Gabriel De la Cruz Ku (ORCID: https://orcid.org/0000-0003-4203-3890)
- Sarah Persing
- Salvatore Nardello
- Sarah Roberts (ORCID: https://orcid.org/0000-0003-2170-9564)
- Saman Namazian
Institutions
- Tufts Medical Center (US)
- University of Massachusetts Chan Medical School (US)
- Universidad Científica del Sur (PE)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2025-11-16
- DOI
- https://doi.org/10.1002/jso.70128
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00